Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effects Of PF-04802540 On Polysomnography Endpoints In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2010
At a glance
- Drugs TS 032 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 07 Apr 2009 Actual patient number (13) added as reported by ClinicalTrials.gov.
- 07 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2008 Status changed from not yet recruiting to recruiting.